Delphi Genetics significantly expands its capacities for cGMP plasmid DNA

Do you need plasmid DNA manufacturing slots, rapidly available, for your gene therapy programs?

You have come to the right place!

Delphi Genetics is currently significantly expanding its production capacities.

Three new flexible suites for single-use manufacturing of High Quality and cGMP plasmid DNA are currently being constructed. The suites are expected to be ready by early 2020, allowing the Belgian CDMO to further respond to its customers’ needs and welcome new partners for long-term relationships.

The fast-growing gene therapy market and our customers’ requirements for a reliable and flexible manufacturing partner have convinced us to invest in three additional suites that will complement our current plasmid DNA service offering” says François Blondel, CEO and Chairman of the Board of Delphi Genetics. “It is really exciting to be an actor in the gene therapy field and to contribute to the success of our partners, delivering promising therapies to the patients”.

Founded in 2001, Delphi Genetics is a GMP approved contract and manufacturing organization (CDMO) with core business and expertise in genetic engineering and plasmid DNA production. The biotech provides maximum flexibility for the production of milligrams to grams of plasmid DNA, up to 50L fermentation scale, single-use.

Stay tuned! More information is coming up …

 

Jean Michel Schaus, Business Development Manager, jmschaus@delphigenetics.com

www.delphigenetics.com